Dr. Komrokji Discusses Molecular Testing for MDS

Rami S. Komrokji, MD, Principal Investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses molecular testing for patients with myelodysplastic syndromes (MDS).

Molecular testing in these patients has been done for many years at diagnosis and now it is important to look at next-generation sequencing to investigate the somatic gene mutations, explains Komrokji.

With the integration of somatic gene mutations, abnormalities can be identified in 80% to 90% of the patients, states Komrokji.